📈 Jumpstart Signal Watchlist — October 01, 2026

🏢 What they do: Paysign, Inc. is a payments technology company that provides prepaid card programs, integrated payment processing, and digital banking/payment solutions for businesses, healthcare and pharmaceutical clients, and government or consumer payout programs.
- 🎯 At/above 3yr high $14.36 (current $14.36) · ⏳ SMA200 $7.28 (current price $14.36 is above) · 💰 Market Cap $811M
- PAYS passed all filters and shows favorable conditions.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 450% (>20%); Revenue growth 48% (>15%); ROE 26% (>15%); Low LT D/E 0.06 (<1.0).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA21 (11.4%)
- 🔔 Strong above EMA50 (19.8%)
- 📈 RSI at 68 showing strength
📢 Sentiment (S): 5/10
- 🗞️ News sentiment is neutral (mixed coverage; ✅×2 ❌×2).
✅ DA Davidson raises Paysign stock price target to $15 on growth outlook — Investing.com.
🤖 DA Davidson raised its price target from $12 to $15 while maintaining a Buy rating, citing Paysign’s growth outlook. The article is dated September 30, though it also shows an October 2 update; the reported rating change is a positive catalyst.
✅ Lake Street Maintains Buy on PaySign, Raises Price Target to $15 — Benzinga.
🤖 Lake Street maintained its Buy rating and raised its price target to $15. The higher target signals a more favorable analyst outlook for PAYS.
❌ Paysign EVP, operations Joan Herman sells $716,899 in shares — Investing.com.
🤖 Paysign EVP Joan Herman sold shares in two September transactions. Insider selling may weigh on sentiment, although the article notes she continued to hold a substantial number of shares.
❌ Paysign chief innovation officer Michael Ngo sells $1.9m in stock — Investing.com.
🤖 Paysign’s chief innovation officer sold 150,000 shares in September, a potentially negative signal for investor sentiment. The article also notes he retained substantial direct and indirect holdings.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $11.29 is 11% below 3yr high $12.66 · ⏳ SMA200 $8.94 (current price $11.29 is above) · 💰 Market Cap $1.9B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×3).
✅ Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages — MarketBeat.
🤖 The article reports a consensus Moderate Buy rating from eight analysts, with six Buy ratings and one Strong Buy. The average 12-month price target of $21.57 is well above the cited recent share price of $10.65.
✅ Raymond James reiterates Vir Biotechnology stock rating on hepatitis delta data — Investing.com.
🤖 Raymond James maintained its Strong Buy rating and $19 price target after a competitor’s trial results, saying those results do not change the outlook for Vir’s pivotal hepatitis delta studies. The analyst expects Vir’s therapies to gain approval, though that remains a forecast rather than a confirmed outcome.
✅ Vir Biotechnology Stock: Astellas Deal Highlights The Platform's Value (NASDAQ:VIR) — Seeking Alpha.
🤖 The article highlights the Astellas partnership, including $335 million in upfront and near-term payments, as validation of Vir’s PRO-XTEN platform. It also points to fully enrolled hepatitis delta Phase 3 trials and a cash runway into the second half of 2028.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $57.94 is 2% below 3yr high $59.13 · ⏳ SMA200 $48.82 (current price $57.94 is above) · 💰 Market Cap $14.4B
- EXEL shows favorable technicals but negative sentiment warrants caution.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 4/10
- 🗞️ News sentiment is negative (mixed coverage; ✅×1 ❌×2 ⚪️×2).
✅ Exelixis Shares Rising on CABOMETYX Revenue — Yahoo Finance.
🤖 The article reports strong CABOMETYX sales and solid second-quarter financial results, including year-over-year product revenue growth. The search result shows a September 30 publication date, though it also notes an update on October 2.
❌ Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? — Zacks.
🤖 The FDA extended its review of zanzalintinib for metastatic colorectal cancer by three months, moving the target action date to March 3, 2027. The delay postpones a potential approval and launch, weighing on near-term growth prospects.
❌ Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib ... — Yahoo Finance.
🤖 The FDA extended its review of zanzalintinib by three months after receiving updated safety and efficacy data, moving the decision date to March 3, 2027. The news was accompanied by a reported 3.5% premarket share decline.
⚪️ Exelixis (NASDAQ:EXEL) Reaches New 52-Week High — MarketBeat.
🤖 The article reports that EXEL reached a new 52-week high, a positive price-performance signal, but notes the consensus rating is Hold and the average price target is below the trading price. The search result lists September 30 as the publication date and October 1 as an update.
⚪️ Exelixis stock hits all-time high at 59.73 USD — Investing.com.
🤖 The article reports a new stock-price high, while also noting that second-quarter revenue slightly missed expectations and the company lowered its full-year revenue outlook. It additionally mentions the three-month FDA review extension for zanzalintinib, tempering the positive price milestone.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: ScanSource is a technology distributor that connects hardware, software, connectivity, and cloud solutions to channel partners and businesses. Its products and services include point-of-sale systems, barcode and data-capture equipment, networking, communications, physical security, payments, and related value-added services.
- 🎯 At/above 3yr high $62.22 (current $62.22) · ⏳ SMA200 $45.64 (current price $62.22 is above) · 💰 Market Cap $1.3B
- SCSC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 55/60
- 🏦 Base breakout (range: 5.5%); Low drawdown (12.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 40% (>20%); Revenue growth 17% (>15%).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA21 (7.5%)
- 🔔 Strong above EMA50 (11.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 68 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ SCSC vs. SYM: Which Stock Is the Better Value Option? — Yahoo Finance.
🤖 The comparison notes ScanSource has a Zacks Rank of #1 (Strong Buy) and a substantially lower forward P/E than Symbotic. The favorable relative valuation and rating are positive signals, though the article is a stock comparison rather than a new company-specific development.
✅ ScanSource (SCSC) Momentum Run Keeps Fair Value In Focus — Yahoo Finance.
🤖 The article highlights recent share-price momentum and a fair-value estimate above the current share price. Its valuation and performance discussion presents a favorable view of the stock.
✅ ScanSource (SCSC) Stock May Still Trade Below Fair Value As Shares Rose 90% — Yahoo Finance.
🤖 The article discusses ScanSource’s strong multi-year share-price gains while questioning whether the stock still trades below fair value. The possibility of further upside supports a positive, though valuation-focused, interpretation.
🍭 Bonus (B): 0/10 — Computers & Software - Wholesale

🏢 What they do: Hewlett Packard Enterprise (HPE) is an enterprise technology company that provides compute, storage, networking, and software solutions designed for hybrid IT environments and AI infrastructure.
- 🎯 At/above 3yr high $64.58 (current $64.58) · ⏳ SMA200 $36.45 (current price $64.58 is above) · 💰 Market Cap $85.8B
- HPE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 49/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 405% (>20%); Revenue growth 34% (>15%); Low LT D/E 0.82 (<1.0); PEG ratio 0.08 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (7.7%)
- 🔔 Strong above EMA50 (16.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Hewlett Packard Enterprise (NYSE:HPE) Given New $83.00 Price Target at Barclays — MarketBeat.
🤖 The article reports favorable analyst sentiment and a consensus Moderate Buy rating. However, the cited analyst target changes are dated September 3, so they are not new developments on the article’s October 1 publication date.
✅ Hewlett Packard Enterprise (NYSE:HPE) Reaches New 52-Week High, Still a Buy — MarketBeat.
🤖 HPE reached a new 52-week high, and the article describes the analyst consensus as Moderate Buy. The price strength and generally favorable ratings are positive signals, though the article also notes mixed individual analyst views.
✅ Can HPE Sustain Its AI Infrastructure Momentum Amid the Capex Cycle — Zacks.
🤖 The article highlights strong AI demand, including a $7.6 billion AI backlog, rising AI Systems orders, and an increased Networks-for-AI target. These indicators suggest momentum in HPE’s AI and networking businesses.
🍭 Bonus (B): 10/10 — Computer & Office Equipment (Technology sector)

🏢 What they do: Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, focused on helping employers manage workplace injuries and employee health. Its services include occupational health centers, onsite employer clinics, telemedicine, workers’ compensation care, and other direct-to-employer health services.
- 🎯 Current $34.97 is 4% below 3yr high $36.37 · ⏳ SMA200 $26.48 (current price $34.97 is above) · 💰 Market Cap $4.5B
- CON shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (6.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 46% (>20%); ROE 42% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 53 in healthy mid-range
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Concentra Group Holdings Parent (CON) Beats Again And Expands In Florida, Is The Stock Still Undervalued? — Yahoo Finance.
🤖 The article highlights Concentra’s second-quarter earnings beat and the opening of a new occupational health center in Daytona Beach, expanding its footprint. It also notes the shares are below the article’s cited fair-value estimate, though the valuation comparison is not a guarantee of future performance.
✅ Concentra Group Stock: Beneficiary Of Increased Injuries, Data Center Capex — Seeking Alpha.
🤖 The analysis cites Concentra’s second-quarter earnings beat, revenue growth, and higher adjusted EBITDA, and points to potential growth from reimbursement increases and acquisitions. It argues that valuation and operating trends support further upside, while reflecting the author’s investment view.
⚪️ Concentra appoints Tanner Newton as CFO (CON:NYSE) — Seeking Alpha.
🤖 Concentra appointed senior vice president of strategy and finance Tanner Newton as executive vice president and CFO, effective November 1, 2026. The article reports a leadership change but provides no specific financial outlook or expected impact.
🍭 Bonus (B): 0/10 — Specialty Outpatient Facilities

🏢 What they do: Five9, Inc. provides cloud contact center software, including its Intelligent CX platform for managing customer interactions across voice and digital channels like chat, email, SMS, and social media. Its products also include AI, automation, analytics, and workforce optimization tools that help businesses run customer service and sales operations.
- 🎯 Current $35.75 is 58% below 3yr high $85.47 · ⏳ SMA200 $22.53 (current price $35.75 is above) · 💰 Market Cap $2.7B
- FIVN shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 300% (>20%); Low LT D/E 0.25 (<1.0); PEG ratio 0.17 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (12.1%)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Five9, Inc. (NASDAQ:FIVN) Receives Consensus Recommendation of Moderate Buy from Analysts — MarketBeat.
🤖 A majority of the 19 covering brokerages recommend buying Five9, and the average 12-month price target is $34.33. The consensus reflects a generally favorable analyst outlook.
✅ Five9 (NASDAQ:FIVN) Reaches New 52-Week High — MarketBeat.
🤖 The article reports that Five9 reached a new 52-week high and notes favorable analyst sentiment and recent price-target increases. The share-price milestone and analyst outlook are positive signals, though the article does not identify a new operating catalyst.
⚪️ Five9 President Andy Dignan Sells Shares for $244510 — Yahoo Finance.
🤖 Five9’s president sold shares under a trading plan adopted in 2025, well before the sale. The report describes a scheduled insider transaction rather than a new company-specific catalyst.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)